Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update
March 02, 2023 07:00 ET
|
Chimerix, Inc.
- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study – – Confirmed Response in Non-H3 K27M Recurrent Glioblastoma...
Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference
February 28, 2023 16:05 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023
February 23, 2023 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update
December 08, 2022 17:00 ET
|
Chimerix, Inc.
– Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis – ...
Chimerix Responds to Rubric Capital Management
November 10, 2022 16:30 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update
November 03, 2022 07:00 ET
|
Chimerix, Inc.
– ONC201 Phase 3 ACTION Study On-Track to Open Enrollment in November – – Meeting with U.S. Food and Drug Administration (FDA) Set for Fourth Quarter – – Strong Financial Position with ~$285...
Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022
October 27, 2022 16:30 ET
|
Chimerix, Inc.
DURHAM, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients...
Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions
September 26, 2022 16:05 ET
|
Chimerix, Inc.
- $238 Million in Upfront Payment Received at Closing with Additional $136.5 Million in Potential Milestone Payments Plus Royalties - DURHAM, N.C., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Chimerix,...
Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...